Wish I had 100k to put into this company!
Israel's IceCure says gets FDA nod to treat tumors in liver, kidney
JERUSALEM (Reuters) - Israel’s IceCure Medical said on Sunday it received U.S. regulatory approval to expand the use of its cryoablation technology to treat benign and cancerous tumors in livers and kidneys, sending its share price up 30%.
Using the IceSense3 system, IceCure said doctors performed the procedures on 146 patients, a majority (103) of whom were under monitoring for almost two years. The company reported that out of the 146 women, one saw the cancer recur.